A patient advocacy organization quoted Natalie Callander, MD, professor (CHS), Hematology, Medical Oncology and Palliative Care, about an ongoing Phase I clinical trial of I-131-CLR1404 to allow targeted delivery of ionizing radiation to myeloma cells.
“We are excited to be developing a new treatment option for this difficult disease. Because of its unique mechanism of action, I-131-CLR1404 may represent an entirely different treatment approach for patients that are no longer responding to currently available therapies,” said Dr. Callendar.
The Phase I trial is being conducted at three myeloma centers. It is testing the best dose, safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone. Myeloma patients must have been previously treated with (or have become intolerant to) an immunomodulator and a proteasome inhibitor.
The ClinicalTrials.gov Identifier number for the trial is NCT02278315. The estimated primary completion date (i.e., the final data collection date for primary outcome measure) was September, 2017.
- "Clinical Trial: Myeloma Cell-Targeted Ionizing Radiation Using I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma," MyelomaCrowd, August 2, 2017
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma, ClinicalTrials.gov
Photo: Micrograph (H&E stain) of a plasmacytoma. CC BY-SA 3.0